Mifeprex patent extension
Executive Summary
Danco Labs expects Mifeprex (mifepristone, RU-486) to receive a two-year patent extension as a result of FDA's reassessment of the regulatory review period for the abortion drug, in lieu of the four-year extension originally expected. FDA said in an Oct. 24 Federal Register notice that it changed its determination of the start date for the Mifeprex IND from 1994 to the pre-Waxman/Hatch date of 1983 (1"The Pink Sheet" Oct. 28, p. 21). A two-year extension will give Mifeprex exclusivity through January 2004...
You may also be interested in...
Danco Mifeprex Patent Extension Will Be Revised After Corcept Objects
The patent life of Danco Labs/The Population Council's Mifeprex (mifepristone, RU-486) will be shortened following a determination by FDA that the abortifacient IND became "effective" in 1983 rather than 1994
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.